Damora Therapeutics Inc
DMRAHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 3:59 PM ET
22.05-1.20 (-5.16%)
2026-11-13 13:15 CET
Market cap
$1.36B
Revenue, TTM
0.00 USD m
Net income, TTM
-291.68 USD m
Free cash flow, TTM
-59.13 USD m
EPS diluted, TTM
-122.94
Price
DMRA against its 20, 50 and 200-day averagesPatternshover a marker to name it
42.5% under the 52-week high of 38.33 on 26 Dec 2025. 52-week low 15.76 on 25 Nov 2025. Last 15 sessions, 23.9% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 63
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
DMRA52-week range, 28% of the way up
15.7638.33
Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Waltham, MA.
| Index | RUT |
|---|---|
| Employees | 7 |
| IPO | Oct 29, 2020 |
| Beta | 1.51 |
| ATR, 14d | 1.76 |
| Rel volume | 0.00 |
| Short float | 9.72% |
| Insider own | 22.08% |
| Inst own | 89.39% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $1.36B |
| Enterprise Value | 967.62M |
| Income | -291.68M |
| Sales | 0.00M |
| Book / share | 5.91 |
| Cash / share | 8.54 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 7 |
| IPO | Oct 29, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 3.73 |
| Price / cash | 2.58 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 14.76 |
| Current Ratio | 14.76 |
| Debt / equity | 0.00 |
| Long-term debt / equity | 0.00 |
| Options and short | No / Yes |
Earnings
| Earnings / share | -122.94 |
|---|---|
| Earnings next year | -2.15 |
| Earnings next quarter | -0.55 |
| Earnings this year | 49.75% |
| Earnings next year | -7.41% |
| Earnings growth, 5 years | 13.44% |
| Past earnings growth | -36.14% -34.72% |
| Past sales growth | - - |
| Earnings vs last year | -916.03% |
| Sales vs last year | - |
| Earnings vs last quarter | 78.08% |
| Sales vs last quarter | - |
| Earnings | Nov 04 AMC |
| Surprise | 17.10% - |
Ownership
| Insiders own | 22.08% |
|---|---|
| Insider trades | 0.09% |
| Institutions own | 89.39% |
| Institution trades | 12.10% |
| Return on assets | -107.36% |
| Return on equity | -116.11% |
| Return on capital | -58.72% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 0.98% |
| 50-day average | -1.21% |
| 200-day average | -13.55% |
Technical
| Shares out | 61.90M |
|---|---|
| Shares floating | 48.25M |
| Short / float | 9.72% |
| Short ratio | 8.53 |
| Short interest | 4.69M |
| 52-week high | 38.33 -42.5% |
| 52-week low | 15.76 +39.9% |
| Volatility | 8.18% 8.09% |
| Average range | 1.76 |
| Strength index | 49.16 |
| Market sensitivity | 1.51 |
| Relative volume | 0.00 |
| Avg Volume | 549.48K |
| Volume | 0 |
Performance
| Perf Week | 0.87% |
|---|---|
| Perf Month | 19.64% |
| Perf Quarter | -28.96% |
| Perf Half Y | -7.66% |
| Perf YTD | -4.17% |
| Perf Year | -6.57% |
| Perf 3Y | 52.07% |
| Perf 5Y | -75.15% |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 46.78 |
| Prev Close | 22.05 |
| Price | 22.05 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 13| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jul 27, 2026 | Initiated | Jefferies | Buy | $50 | +126.8% |
| Jun 11, 2026 | Initiated | H.C. Wainwright | Buy | $45 | +104.1% |
| Jun 08, 2026 | Initiated | TD Cowen | Buy | ||
| May 28, 2026 | Initiated | Wedbush | Outperform | $35 | +58.7% |
| Apr 24, 2026 | Initiated | RBC Capital Mkts | Outperform | $40 | +81.4% |
| Mar 25, 2026 | Initiated | Evercore ISI | Outperform | $46 | +108.6% |
| Feb 17, 2026 | Initiated | UBS | Buy | $45 | +104.1% |
| Jan 07, 2026 | Initiated | Leerink Partners | Outperform | $46 | +108.6% |
| Dec 01, 2025 | Initiated | Guggenheim | Buy | $32 | +45.1% |
| Apr 26, 2021 | Resumed | Credit Suisse | Outperform | $12 | -45.6% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| GERN | Geron Corp | 625.42M |
| SNDX | Syndax Pharmaceuticals Inc | 868.77M |
| KURA | Kura Oncology Inc | 700.18M |
| AGIO | Agios Pharmaceuticals Inc | 1.90B |
| IRON | Disc Medicine Inc | 3.79B |
| SLS | SELLAS Life Sciences Group Inc | 1.91B |
| COAG | Hemab Therapeutics Holdings Inc | 1.84B |
| KROS | Keros Therapeutics Inc | 197.81M |
| BLSM | BlossomHill Therapeutics Inc | 471.69M |
| PRLD | Prelude Therapeutics Inc | 277.69M |
Insider trading
9 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | Director, President and CEO | Sep 25 '26 | Buy | 20.23 | 12,500 | 252,875 | 512,500 | Sep 28 07:00 AM |
| Firmani Lori | Officer | Aug 05 '26 | Proposed Sale | 31.10 | 1,800 | 55,980 | Aug 06 11:34 AM | |
| Winslow Garrett | General Counsel | Jul 06 '26 | Sale | 29.98 | 245 | 7,345 | 2,289 | Jul 07 08:00 PM |
| Firmani Lori | Officer | Jun 22 '26 | Proposed Sale | 25.36 | 7,615 | 193,140 | Jun 22 02:27 PM | |
| Bruno Julianne | Director | Feb 09 '26 | Option Exercise | 0.00 | 129,000 | 0 | 137,032 | Feb 12 06:05 AM |
| Fairmount Funds Management LLC | Director | Feb 09 '26 | Option Exercise | 0.00 | 8,713,000 | 0 | 5,809,000 | Feb 12 06:03 AM |
| Schambye Hans T. | Chief Executive Officer | Jan 02 '26 | Sale | 21.38 | 700 | 14,966 | 4,682 | Jan 06 04:30 PM |
| Winslow Garrett | General Counsel | Jan 02 '26 | Sale | 21.38 | 255 | 5,452 | 1,854 | Jan 06 04:30 PM |
| Firmani Lori | Chief Financial Officer | Jan 02 '26 | Sale | 21.41 | 135 | 2,890 | 931 | Jan 06 04:30 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | AUM: 96.50B |
| VTWG | Vanguard Russell 2000 Growth Index ETF | AUM: 1.43B |
| SCHB | Schwab U.S. Broad Market ETF | AUM: 44.65B |
News
latest 14 of 200- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.42%
- Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
- Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting (GlobeNewswire)
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
- Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis (GlobeNewswire)
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.11%
- Damora Announces Redomestication from Delaware to Cayman Islands (GlobeNewswire)
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.67%
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.21%
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Quarterly earnings
2026Q3 EPS -0.400 beat -0.483, from -2.360 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-04 16:30 | -0.400 | -0.483 | -0.400 | 0.00 | 0.00 | EPS -17.1% · sales - | vs 2025Q3, year-ago quarter · EPS -83.1% · sales - | 8 EPS · 5 sales | Open +0.92% vs SPY -0.17%. Close -4.71% vs SPY -4.41% |
| 2026Q2ended 2026-06-30 | 2026-08-10 16:30 | -0.414 | -0.414 | -0.510 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2025Q2, year-ago quarter · EPS -84.1% · sales - | 8 EPS · 5 sales | Open +1.18% vs SPY +0.19%. Close +2.78% vs SPY -0.32% |
| 2026Q1ended 2026-03-31 | 2026-05-12 16:30 | -0.620 | -0.388 | -0.809 | 0.00 | 0.00 | EPS +59.9% · sales - | vs 2025Q1, year-ago quarter · EPS -67.7% · sales - | 4 EPS · 2 sales | Open +0.43% vs SPY +0.04%. Close +4.63% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-19 16:30 | -3.243 | 0.902 | -121.1 | 0.00 | 0.00 | EPS -459.5% · sales - | - | 3 EPS · 2 sales | Open +5.16% vs SPY -0.50%. Close -5.52% vs SPY -1.70% |
| 2025Q3ended 2025-09-30 | 2025-11-06 16:30 | -2.360 | - | -2.361 | 0.00 | - | EPS - · sales - | vs 2024Q3, year-ago quarter · EPS -30.4% · sales - | - | Open -12.89% vs SPY -0.36%. Close -14.95% vs SPY +0.10% |
| 2025Q2ended 2025-06-30 | 2025-08-05 16:30 | -2.600 | - | -2.599 | 0.00 | - | EPS - · sales - | vs 2024Q2, year-ago quarter · EPS -47.2% · sales - | - | Open -5.15% vs SPY +0.17%. Close 0.00% vs SPY +0.77% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -1.920 | - | -1.916 | 0.00 | - | EPS - · sales - | vs 2024Q1, year-ago quarter · EPS -98.5% · sales - | - | Open 0.00% vs SPY +0.25%. Close -3.35% vs SPY -0.13% |
| 2024Q3ended 2024-09-30 | 2024-11-01 08:30 | -3.390 | -3.700 | -3.391 | 0.00 | 0.00 | EPS -8.4% · sales - | vs 2023Q3, year-ago quarter · EPS -54.8% · sales - | 1 | Open +0.58% vs SPY +0.47%. Close -1.46% vs SPY +0.42% |
| 2024Q2ended 2024-06-30 | 2024-07-31 12:00 | -4.920 | -6.035 | -4.922 | 0.00 | 0.00 | EPS -18.5% · sales - | vs 2023Q2, year-ago quarter · EPS -52.0% · sales - | 1 | Open -1.07% vs SPY +1.29%. Close +0.53% vs SPY +1.63% |
| 2024Q1ended 2024-03-31 | 2024-04-26 12:00 | -126.25 | -256.25 | -5.050 | 0.00 | - | EPS -50.7% · sales - | vs 2023Q1, year-ago quarter · EPS +890.2% · sales - | 1 | Open +1.21% vs SPY +0.57%. Close +5.37% vs SPY +0.95% |
| 2023Q4ended 2023-12-31 | 2024-03-25 12:00 | -8.750 | -8.750 | -5.971 | - | 0.00 | EPS 0.0% · sales - | vs 2022Q4, year-ago quarter · EPS -36.4% · sales - | 1 | Open -0.37% vs SPY -0.27%. Close -5.38% vs SPY -0.28% |
| 2023Q3ended 2023-09-30 | 2023-12-15 12:00 | -7.500 | -8.500 | -7.504 | 0.00 | 0.00 | EPS -11.8% · sales - | vs 2022Q3, year-ago quarter · EPS -44.4% · sales - | 2 EPS · 1 sales | Open -1.60% vs SPY -0.53%. Close -2.72% vs SPY -0.57% |
| 2023Q2ended 2023-06-30 | 2023-07-31 16:30 | -10.250 | -14.668 | -10.184 | 0.00 | 0.00 | EPS -30.1% · sales - | vs 2022Q2, year-ago quarter · EPS -38.8% · sales - | 3 EPS · 2 sales | - |
| 2023Q1ended 2023-03-31 | 2023-04-28 08:30 | -12.750 | -15.625 | -12.654 | 0.00 | 0.00 | EPS -18.4% · sales - | vs 2022Q1, year-ago quarter · EPS -23.9% · sales - | 2 EPS · 3 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-09 08:30 | -13.750 | -14.250 | -13.719 | 0.00 | 0.00 | EPS -3.5% · sales - | vs 2021Q4, year-ago quarter · EPS +3.8% · sales - | 1 | - |
| 2022Q3ended 2022-09-30 | 2022-11-08 08:30 | -13.500 | -17.000 | -13.465 | 0.00 | 0.00 | EPS -20.6% · sales - | vs 2021Q3, year-ago quarter · EPS +8.0% · sales - | 1 EPS · 2 sales | - |
Annual earnings
2025FY EPS -3.980 missed -1.936, from -18.530 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -2.586 | - | - | 49.63 | - |
| 2029FYestimate | - | -2.549 | - | - | 0.00 | - |
| 2028FYestimate | - | -2.581 | - | - | 0.00 | - |
| 2027FYestimate | - | -2.148 | - | - | 0.00 | - |
| 2026FYestimate | - | -2.000 | - | - | 0.00 | - |
| 2025FY | -3.980 | -1.936 | -3.980 | 0.00 | 0.00 | - |
| 2024FY | -18.530 | -15.910 | -18.527 | 0.00 | 0.00 | - |
| 2023FY | -36.080 | -39.000 | -36.081 | 0.00 | 0.00 | - |
| 2022FY | -60.750 | -61.250 | -60.632 | 0.00 | 0.00 | - |
| 2021FY | -51.250 | -53.220 | -51.216 | 0.00 | 0.00 | - |
| 2020FY | -190.49 | -163 | -34.476 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.00 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-05 | -2.00 | -1.9% |
| 2026Q4 | E | per share | 2026-11-05 | -0.55 | +8.0% |
| 2026FY | R | per share | 2026-11-05 | -2.19 | +1.0% |
| 2026Q4 | R | per share | 2026-11-05 | -0.61 | +18.9% |
| 2026Q4 | S | per share | 2026-11-05 | 0.00 | - |
| 2026Q3 | E | per share | 2026-10-28 | -0.48 | 0.0% |
| 2026Q3 | R | per share | 2026-10-25 | -0.49 | 0.0% |
| 2026FY | S | per share | 2026-08-11 | 0.00 | - |
| 2026Q3 | S | per share | 2026-08-11 | 0.00 | - |
| 2026Q2 | E | per share | 2026-08-10 | -0.41 | +0.7% |
| 2026Q2 | R | per share | 2026-08-10 | -0.41 | -3.0% |
| 2026Q2 | S | per share | 2026-06-10 | 0.00 | - |
| 2026Q1 | E | per share | 2026-04-22 | -0.39 | +29.1% |
| 2026Q1 | R | per share | 2026-03-20 | -0.45 | +269.8% |
| 2026Q1 | S | per share | 2026-03-20 | 0.00 | - |
| 2025FY | E | per share | 2026-03-18 | -1.94 | +102.5% |
| 2025Q4 | E | per share | 2026-03-18 | 0.90 | -936.1% |
| 2025FY | R | per share | 2026-02-17 | -0.91 | -14.6% |
| 2025Q4 | R | per share | 2026-02-17 | -0.10 | -30.9% |
| 2025FY | S | per share | 2026-02-17 | 0.00 | - |
| 2025Q4 | S | per share | 2026-01-06 | 0.00 | - |
| 2024FY | E | per share | 2025-03-06 | -16.23 | +2.0% |
| 2024Q4 | E | per share | 2025-03-06 | -3.12 | +5.1% |
| 2024FY | S | per share | 2025-03-06 | 0.00 | - |
| 2024Q4 | S | per share | 2024-11-01 | 0.00 | - |
| 2024Q3 | E | per share | 2024-10-15 | -3.70 | -12.9% |
| 2024Q2 | E | per share | 2024-08-14 | -0.20 | -17.1% |
| 2024Q3 | S | per share | 2024-07-31 | 0.00 | - |
| 2024Q2 | S | per share | 2024-06-05 | 0.00 | - |
| 2024Q1 | E | per share | 2024-03-25 | -0.41 | 0.0% |
| 2023FY | E | per share | 2024-03-05 | -1.56 | 0.0% |
| 2023FY | S | per share | 2024-02-22 | 0.00 | - |
| 2024FY | R | per share | 2023-10-11 | -25.25 | 0.0% |
| 2024Q3 | R | per share | 2023-10-11 | -5.75 | 0.0% |
| 2023FY | R | per share | 2023-08-31 | -1.34 | -26.2% |
| 2024Q2 | R | per share | 2023-08-29 | -0.28 | 0.0% |
| 2024Q1 | R | per share | 2023-08-14 | -0.28 | -51.7% |
| 2024Q1 | S | per share | 2023-08-01 | 0.00 | - |
Estimate history
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -18.68 | -41.347 | -34.476 | -51.216 | -60.632 | -36.081 | -18.527 | -152.99 | -122.9392 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | - | 62 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -3.391 | -5.224 | -1.916 | -2.599 | -2.361 | -121.103 | -0.809 | -0.51 | -0.517 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 1 | 1 | 1 | 1 | 1 | 2 | 60 | 62 | 62 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.35 | 0.03-83.3% | 0.18-78.3% | 0.83+69.4% | 0.49+11.4% | 0.44+131.6% | 0.19+72.7% | 0.11 | 0.00 |
| Gross Profit | -0.35 | -0.03 | -0.18 | -0.83 | -0.49 | -0.44 | -0.19 | -0.11 | 0.00 |
| Selling, General and Administrative Excl. Other | 129.70 | 36.53+118.5% | 16.72-53.1% | 35.63-41.3% | 60.72+17.2% | 51.79+54.8% | 33.45-13.9% | 38.86+201.0% | 12.91 |
| Research and Development | 98.11 | 26.88+320.0% | 6.40-73.1% | 23.77-50.7% | 48.21+25.3% | 38.49+56.3% | 24.63-32.6% | 36.53+262.0% | 10.09 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -130.05 | -36.56 | -16.90 | -36.46 | -61.21 | -52.23 | -33.64 | -38.97 | -12.91 |
| Interest Expense | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 2.97 |
| Unusual Expense | 174.31 | 174.31+3152.1% | 5.36+55.4% | 3.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -291.34 | -209.79 | -21.40 | -38.35 | -61.62 | -51.75 | -34.84 | -36.51 | -15.87 |
| Income Taxes | 0.34 | 0.05+25.0% | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -291.68 | -209.84 | -21.44 | -38.35 | -61.62 | -51.75 | -34.84 | -36.51 | -15.87 |
| Net Income From Continuing Operations | -291.68 | -209.84 | -21.44 | -38.35 | -61.62 | -51.75 | -34.84 | -36.51 | -15.87 |
| Net Income | -291.68 | -209.84 | -21.44 | -38.35 | -61.62 | -51.75 | -34.84 | -42.07 | -19.00 |
| EPS (Recurring) per share | -2.74 | -64.03 | -15.28 | -33.81 | -60.63 | -51.22 | -34.48 | -41.35 | -18.68 |
| EPS (Basic, Before Extraordinaries) per share | -122.94 | -152.99 | -18.53 | -36.08 | -60.63 | -51.22 | -34.48 | -41.35 | -18.68 |
| EPS (Diluted) per share | -122.94 | -152.99 | -18.53 | -36.08 | -60.63 | -51.22 | -34.48 | -41.35 | -18.68 |
| EBITDA | -129.70 | -36.53 | -16.72 | -35.63 | -60.72 | -51.79 | -33.45 | -38.86 | -12.91 |
| Non-Operating Income (Expense) | 13.02 | 1.08+25.6% | 0.86-44.9% | 1.56 | -0.42-189.4% | 0.47 | -1.20-148.8% | 2.46+24500.0% | 0.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 23.04 | 0.79-69.1% | 2.56-52.9% | 5.43-2.5% | 5.57+24.3% | 4.48+348.0% | 1.00 | - | 0.08 |
| Shares Outstanding million shares | 61.92 | 1.66+25.8% | 1.32+22.2% | 1.08+4.9% | 1.03+2.0% | 1.010.0% | 1.01-1.0% | 1.020.0% | 1.02 |
| Market Capitalization | 1,365.40 | 1,365.40+22210.5% | 6.12-68.6% | 19.52-33.7% | 29.42-61.6% | 76.54-75.8% | 316.03-5.6% | 334.71 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.26+2500.0% | 0.010.0% | 0.07+600.0% | 0.010.0% | 0.01-83.3% | 0.01-87.5% | 0.01-90.0% | 0.01-95.7% |
| Gross Profit | -0.26 | -0.01 | -0.07 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Selling, General and Administrative Excl. Other | 36.60+1061.9% | 34.98+925.8% | 30.74+1086.9% | 27.38+914.1% | 3.15-16.7% | 3.41-24.7% | 2.59-54.1% | 2.70-52.8% |
| Research and Development | 25.48+1694.4% | 25.54+1637.4% | 23.78+3397.1% | 23.32+2208.9% | 1.42+30.3% | 1.47-19.7% | 0.68-72.4% | 1.01-63.5% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -36.86 | -34.99 | -30.81 | -27.39 | -3.16 | -3.42 | -2.60 | -2.71 |
| Interest Expense | 0.00 | - | - | - | - | - | - | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 174.31+3870.6% | 0.00 | 0.00-100.0% | 0.00 | 4.39+509.7% |
| Net Income Before Taxes | -31.99 | -30.92 | -27.74 | -200.69 | -3.13 | -3.43 | -2.53 | -6.75 |
| Income Taxes | 0.00 | 0.26 | 0.04 | 0.04 | 0.00-100.0% | 0.00-100.0% | 0.00 | -0.01 |
| Consolidated Net Income | -31.99 | -31.17 | -27.78 | -200.74 | -3.13 | -3.44 | -2.53 | -6.74 |
| Net Income From Continuing Operations | -31.99 | -31.17 | -27.78 | -200.74 | -3.13 | -3.44 | -2.53 | -6.74 |
| Net Income | -31.99 | -31.17 | -27.78 | -200.74 | -3.13 | -3.44 | -2.53 | -6.74 |
| EPS (Recurring) per share | -0.52 | -0.51 | -0.81 | -47.49 | -2.36 | -2.60 | -1.92 | -2.84 |
| EPS (Basic, Before Extraordinaries) per share | -0.52 | -0.51 | -0.81 | -121.10 | -2.36 | -2.60 | -1.92 | -5.22 |
| EPS (Diluted) per share | -0.52 | -0.51 | -0.81 | -121.10 | -2.36 | -2.60 | -1.92 | -5.22 |
| EBITDA | -36.60 | -34.98 | -30.74 | -27.38 | -3.15 | -3.41 | -2.59 | -2.70 |
| Non-Operating Income (Expense) | 4.87+24250.0% | 4.08 | 3.07+4285.7% | 1.00+185.7% | 0.02 | -0.01-103.6% | 0.07-73.1% | 0.35+75.0% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 7.80+4775.0% | 8.44+5928.6% | 6.41+4478.6% | 0.38+58.3% | 0.16-70.4% | 0.14-80.0% | 0.14-89.7% | 0.24-78.0% |
| Shares Outstanding million shares | 61.92+4555.6% | 61.75+4578.0% | 60.32+4469.7% | 1.66+25.8% | 1.33+6.4% | 1.32+22.2% | 1.32+22.2% | 1.32+22.2% |
| Market Capitalization | 1,365.40+27595.7% | 1,601.47+35409.3% | 1,561.85+37993.9% | 36.70+499.7% | 4.93-67.5% | 4.51-64.9% | 4.10-80.6% | 6.12-68.6% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 257.62+1716.8% | 14.18-57.2% | 33.15-45.0% | 60.22-39.9% | 100.19-38.8% | 163.58+1348.9% | 11.29-63.6% | 30.99 |
| Short Term Receivables | 0.90+2.3% | 0.88-48.8% | 1.72+24.6% | 1.38-39.5% | 2.28+3.2% | 2.21-94.6% | 41.13+4054.5% | 0.99 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.90+6.7% | 1.78-6.8% | 1.91-17.3% | 2.31-69.7% | 7.63+118.0% | 3.50-4.4% | 3.66+22.8% | 2.98 |
| Total Current Assets | 260.42+1446.4% | 16.84-54.2% | 36.77-42.5% | 63.91-42.0% | 110.10-35.0% | 169.29+201.9% | 56.08+60.4% | 34.96 |
| Net Property, Plant & Equipment | 0.10-23.1% | 0.13-60.6% | 0.33-71.8% | 1.17+12.5% | 1.04+16.9% | 0.89+196.7% | 0.30 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00-100.0% | 5.83-35.6% | 9.05+3520.0% | 0.25+8.7% | 0.23+64.3% | 0.14 |
| Intangible Assets | 0.00 | - | - | - | - | - | 0.00 | 0.00 |
| Other Assets | 0.00-100.0% | 0.16-85.8% | 1.13-50.4% | 2.28+12.3% | 2.03+75.0% | 1.16 | 0.00 | 0.00 |
| Total Assets | 260.53+1420.9% | 17.13-55.2% | 38.23-47.8% | 73.19-40.1% | 122.22-28.8% | 171.60+203.1% | 56.61+61.3% | 35.10 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.010.0% | 0.01-94.4% | 0.18-62.5% | 0.48+20.0% | 0.40+8.1% | 0.37+311.1% | 0.09 | 0.00 |
| Accounts Payable | 0.44+15.8% | 0.38-77.6% | 1.70-49.3% | 3.35+119.0% | 1.53-46.3% | 2.85-14.4% | 3.33+136.2% | 1.41 |
| Other Current Liabilities | 19.61+2321.0% | 0.81-79.4% | 3.94-45.9% | 7.28+178.9% | 2.61+11.5% | 2.34-48.1% | 4.51+48.8% | 3.03 |
| Total Current Liabilities | 20.07+1572.5% | 1.20-79.4% | 5.83-47.5% | 11.11+144.7% | 4.54-18.5% | 5.57-29.8% | 7.93+78.6% | 4.44 |
| Long Term Debt | 1.39-2.1% | 1.42+1928.6% | 0.07-78.8% | 0.33-26.7% | 0.45-16.7% | 0.54+157.1% | 0.21 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.03-25.0% | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 21.49+707.9% | 2.66-54.9% | 5.90-48.4% | 11.44+129.3% | 4.99-18.3% | 6.11-24.9% | 8.14+83.3% | 4.44 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 414.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 119.62+85.5% | 64.50 |
| Common Equity | -175.87-1315.4% | 14.47-55.2% | 32.33-47.6% | 61.75-47.3% | 117.22-29.2% | 165.49 | -71.15 | -33.84 |
| Total Shareholders Equity | 239.04+1552.0% | 14.47-55.2% | 32.33-47.6% | 61.75-47.3% | 117.22-29.2% | 165.49+241.4% | 48.47+58.1% | 30.66 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 239.04+1552.0% | 14.47-55.2% | 32.33-47.6% | 61.75-47.3% | 117.22-29.2% | 165.49+241.4% | 48.47+58.1% | 30.66 |
| Total Liabilities & Stockholders Equity | 260.53+1420.9% | 17.13-55.2% | 38.23-47.8% | 73.19-40.1% | 122.22-28.8% | 171.60+203.1% | 56.61+61.3% | 35.10 |
| Book Value Per Share per share | -106.10-1065.4% | 10.99-63.1% | 29.81-50.5% | 60.18-48.1% | 116.01-29.2% | 163.77 | -69.93 | -33.26 |
| Tangible Book Value Per Share per share | -106.10-1065.4% | 10.99-63.1% | 29.81-50.5% | 60.18-48.1% | 116.01-29.2% | 163.77 | -69.93 | -33.26 |
| Full-Time Employees people | 7+40.0% | 5-61.5% | 13-71.1% | 45+12.5% | 40+42.9% | 28+33.3% | 21 | - |
| Price to Book Ratio ratio | 3.73 | 0.28 | 0.52 | 0.40 | 0.65 | 1.91 | -3.65 | - |
| Return on Assets % | -151.15 | -77.45 | -68.84 | -63.07 | -35.23 | -30.53 | -79.61 | - |
| Return on Equity % | -165.55 | -91.62 | -81.52 | -68.86 | -36.61 | -32.56 | -92.27 | - |
| Return on Invested Capital % | -87.28 | -134.90 | -118.37 | -99.26 | -43.98 | -20.98 | -74.99 | -51.76 |
| Quick Ratio ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 | 30.42 | 7.07 | 7.87 |
| Current Ratio ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 | 30.42 | 7.07 | 7.87 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -291.68 | -209.84 | -21.44 | -38.35 | -61.62 | -51.75 | -34.84 | -36.51 | -15.87 |
| Depreciation | 0.35 | 0.03-83.3% | 0.18-78.3% | 0.83+69.4% | 0.49+11.4% | 0.44+131.6% | 0.19+72.7% | 0.11 | 0.00 |
| Other Funds (Non Cash) | 199.93 | 184.72+3385.3% | 5.30+6.4% | 4.98-20.4% | 6.26+11.2% | 5.63+441.3% | 1.04-93.0% | 14.88+378.5% | 3.11 |
| Funds from Operations | -91.40 | -25.09 | -15.96 | -32.54 | -54.87 | -45.68 | -33.61 | -21.52 | -12.76 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 32.27 | 18.36 | -2.67 | -4.37-136.6% | 11.94 | -6.62 | -4.59-309.6% | 2.19 | -0.93 |
| Cash from Operating Activities | -59.13 | -6.73 | -18.62 | -36.91 | -42.93 | -52.31 | -38.20 | -19.33 | -13.69 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 | -0.22 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.33 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00-100.0% | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -196.13 | -17.37-249.1% | 11.65-47.6% | 22.25+76.9% | 12.58 | -47.83 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -196.88 | -17.37 | 0.00 | -25.94 | -44.87 | -84.21 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.75 | 0.00-100.0% | 11.65-75.8% | 48.18-16.1% | 57.45+57.9% | 36.38 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -196.13 | -17.37-249.1% | 11.65-47.8% | 22.33+80.4% | 12.38 | -48.05 | 0.00 | -0.33 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 597.39 | 266.84 | 0.00-100.0% | 2.88+464.7% | 0.51 | 0.00-100.0% | 187.39 | 0.00-100.0% | 34.36 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 597.39 | 266.84 | 0.00-100.0% | 2.88+464.7% | 0.51 | 0.00-100.0% | 187.39 | 0.00-100.0% | 34.36 |
| Proceedsfrom Stock Options | 596.65 | 266.81 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 187.39 | 0.00-100.0% | 34.36 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 8.51 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 8.51 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 8.51 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 597.39 | 266.84 | 0.00-100.0% | 2.88+464.7% | 0.51 | 0.00-100.0% | 187.39 | 0.00-100.0% | 42.87 |
| Exchange Rate Effect | -0.08 | 0.70 | -0.32-184.2% | 0.38+46.2% | 0.26 | -0.92-129.5% | 3.12+6140.0% | 0.05+150.0% | 0.02 |
| Net Change in Cash | 342.05 | 243.45 | -7.29 | -11.32 | -29.78 | -101.27-166.5% | 152.31 | -19.61-167.1% | 29.21 |
| Free Cash Flow | -59.13 | -6.73 | -18.62 | -36.91 | -43.13 | -52.53 | -38.20 | -19.33 | -13.69 |
| Preferred Dividends (Cash Flow) | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 528.48+6844.5% | 540.51+5193.9% | 532.90+4363.1% | 257.62+1716.8% | 7.61-61.3% | 10.21-55.3% | 11.94-56.1% | 14.18-57.2% |
| Short Term Receivables | 0.84-15.2% | 0.88-11.1% | 0.89-3.3% | 0.90+2.3% | 0.99-18.2% | 0.99-42.4% | 0.92-45.9% | 0.88-48.8% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.54-54.6% | 2.19+525.7% | 1.61+198.1% | 1.90+6.7% | 1.19+310.3% | 0.35-39.7% | 0.54-67.7% | 1.78-6.8% |
| Total Current Assets | 529.86+5312.3% | 543.59+4606.4% | 535.41+3895.6% | 260.42+1446.4% | 9.79-53.8% | 11.55-54.1% | 13.40-56.1% | 16.84-54.2% |
| Net Property, Plant & Equipment | 0.83+654.5% | 0.00-100.0% | 0.00-100.0% | 0.10-23.1% | 0.11+22.2% | 0.12-14.3% | 0.12-47.8% | 0.13-60.6% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | 0.00 | - | - | - | - |
| Other Assets | 1.94+131.0% | 0.05-97.5% | 0.03-98.4% | 0.00-100.0% | 0.84-60.0% | 2.02+1.5% | 1.84+7.6% | 0.16-85.8% |
| Total Assets | 532.63+4859.3% | 543.64+3871.1% | 535.44+3383.7% | 260.53+1420.9% | 10.74-54.1% | 13.69-49.9% | 15.37-52.7% | 17.13-55.2% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.15+1400.0% | 0.00-100.0% | 0.00-100.0% | 0.010.0% | 0.01-66.7% | 0.01-87.5% | 0.01-93.3% | 0.01-94.4% |
| Accounts Payable | 6.08+1069.2% | 3.48+357.9% | 0.82+134.3% | 0.44+15.8% | 0.52+4.0% | 0.76+5.6% | 0.35-79.0% | 0.38-77.6% |
| Other Current Liabilities | 29.66+1319.1% | 24.07+1194.1% | 22.99+1848.3% | 19.61+2321.0% | 2.09+9.4% | 1.86-36.1% | 1.18-52.8% | 0.81-79.4% |
| Total Current Liabilities | 35.89+1269.8% | 27.55+947.5% | 23.81+1436.1% | 20.07+1572.5% | 2.62+7.4% | 2.63-29.1% | 1.55-64.1% | 1.20-79.4% |
| Long Term Debt | 0.95-32.1% | 0.00-100.0% | 1.34-5.6% | 1.39-2.1% | 1.40 | 1.40 | 1.42 | 1.42+1928.6% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.03-40.0% | 0.03-40.0% | 0.03-25.0% | 0.03-25.0% | 0.05 | 0.05 | 0.04 | 0.04 |
| Total Liabilities | 36.87+805.9% | 27.58+576.0% | 25.18+733.8% | 21.49+707.9% | 4.07+66.8% | 4.08+10.0% | 3.02-30.1% | 2.66-54.9% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 130.00 | 130.00 | 131.11 | 414.91 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 365.76+5383.7% | 386.06+3917.3% | 379.15+2970.0% | -175.87-1315.4% | 6.67-68.1% | 9.61-59.3% | 12.35-56.1% | 14.47-55.2% |
| Total Shareholders Equity | 495.76+7332.7% | 516.06+5270.0% | 510.26+4031.7% | 239.04+1552.0% | 6.67-68.1% | 9.61-59.3% | 12.35-56.1% | 14.47-55.2% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 495.76+7332.7% | 516.06+5270.0% | 510.26+4031.7% | 239.04+1552.0% | 6.67-68.1% | 9.61-59.3% | 12.35-56.1% | 14.47-55.2% |
| Total Liabilities & Stockholders Equity | 532.63+4859.3% | 543.64+3871.1% | 535.44+3383.7% | 260.53+1420.9% | 10.74-54.1% | 13.69-49.9% | 15.37-52.7% | 17.13-55.2% |
| Book Value Per Share per share | 5.91+17.7% | 6.25-13.9% | 6.29-32.7% | -106.10-1065.4% | 5.02-69.9% | 7.26-66.6% | 9.34-64.0% | 10.99-63.1% |
| Tangible Book Value Per Share per share | 5.91+17.7% | 6.25-13.9% | 6.29-32.7% | -106.10-1065.4% | 5.02-69.9% | 7.26-66.6% | 9.34-64.0% | 10.99-63.1% |
| Full-Time Employees people | - | - | - | 7+40.0% | - | - | - | 5-61.5% |
| Price to Book Ratio ratio | 3.73 | 4.14 | -0.24 | 4.58 | 0.51 | 0.37 | 0.28 | 0.28 |
| Return on Assets % | -107.36 | -94.32 | -85.36 | -151.15 | -92.89 | -80.97 | -77.32 | -77.45 |
| Return on Equity % | -116.11 | -100.00 | -89.97 | -165.55 | -114.81 | -99.96 | -91.32 | -91.62 |
| Return on Invested Capital % | -6.44 | -6.04 | -5.43 | -83.49 | -38.85 | -31.21 | -18.40 | -42.42 |
| Quick Ratio ratio | 14.76 | 19.73 | 22.48 | 12.98 | 3.73 | 4.39 | 8.64 | 14.07 |
| Current Ratio ratio | 14.76 | 19.73 | 22.48 | 12.98 | 3.73 | 4.39 | 8.64 | 14.07 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -31.99 | -31.17 | -27.78 | -200.74 | -3.13 | -3.44 | -2.53 | -6.74 |
| Depreciation | 0.26+2500.0% | 0.010.0% | 0.07+600.0% | 0.01 | 0.01-83.3% | 0.01-87.5% | 0.01-90.0% | -0.05-121.7% |
| Other Funds (Non Cash) | 6.50+3723.5% | 6.14+3511.8% | 3.13+1390.5% | 184.16+8233.0% | 0.17-77.9% | 0.17-82.7% | 0.21-84.4% | 2.21+118.8% |
| Funds from Operations | -25.23 | -25.02 | -24.58 | -16.57 | -2.95 | -3.25 | -2.32 | -4.59 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 8.00+2324.2% | 3.15+208.8% | 3.98 | 17.14 | 0.33 | 1.02+466.7% | -0.12 | -0.35 |
| Cash from Operating Activities | -17.23 | -21.87 | -20.60 | 0.57 | -2.62 | -2.24 | -2.44 | -4.94 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Purchase or Sale of Investments | -178.75 | 0.00 | 0.00 | -17.37 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Purchase of Investments | -179.50 | 0.00 | 0.00 | -17.37 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -178.75 | 0.00 | 0.00 | -17.37 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 5.12 | 29.50 | 295.92 | 266.84 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 5.12 | 29.50 | 295.92 | 266.84 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 5.07 | 29.28 | 295.50 | 266.81 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 5.12 | 29.50 | 295.92 | 266.84 | 0.00 | 0.00 | 0.00 | 0.00 |
| Exchange Rate Effect | 0.010.0% | -0.02-103.9% | -0.05-125.0% | -0.02 | 0.01-97.9% | 0.51 | 0.20 | -0.57-303.6% |
| Net Change in Cash | -190.86 | 7.62 | 275.27 | 250.02 | -2.60 | -1.73-197.7% | -2.24 | -5.50 |
| Free Cash Flow | -17.23 | -21.87 | -20.60 | 0.57 | -2.62 | -2.24 | -2.44 | -4.94 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 9.72% | 4.7M | 48.3M | 522.73K |
| 2026-10-15 | 10.71% | 5.2M | 48.1M | 520.86K |
| 2026-09-30 | 9.84% | 4.7M | 48.1M | 540.71K |
| 2026-09-15 | 9.83% | 4.7M | 48.1M | 594.08K |
| 2026-08-31 | 8.58% | 4.1M | 48.1M | 564.65K |
| 2026-08-14 | 10.78% | 4.7M | 44.0M | 574.57K |
| 2026-07-31 | 10.64% | 4.9M | 46.0M | 585.38K |
| 2026-07-15 | 10.19% | 4.7M | 46.0M | 551.47K |
| 2026-06-30 | 7.76% | 3.6M | 46.0M | 490.96K |
| 2026-06-15 | 2.85% | 1.3M | 46.0M | 327.95K |
| 2026-05-29 | 3.05% | 1.4M | 46.0M | 299.91K |
| 2026-05-15 | 2.83% | 1.3M | 45.6M | 296.71K |
| 2026-04-30 | 2.32% | 1.2M | 51.4M | 301.91K |
| 2026-04-15 | 2.00% | 1.1M | 55.7M | 272.76K |
| 2026-03-31 | 1.49% | 0.8M | 55.7M | 237.79K |
| 2026-03-13 | 0.77% | 0.4M | 55.7M | 185.47K |
| 2026-02-13 | 18.72% | 0.3M | 1.5M | 168.79K |
| 2026-01-30 | 17.47% | 0.1M | 0.9M | 1.14M |
| 2026-01-15 | 16.13% | 0.2M | 1.1M | 1.14M |
| 2025-12-31 | 13.37% | 0.2M | 1.3M | 2.59M |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-09-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-25 | SEC |
| 2026-08-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-13 | 3 | Initial statement of beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-12 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | POSASR | Post-effective amendment to an automatic shelf registration statement of Form S-3ASR or Form F-3ASR | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | S-8 POS | Post-effective amendment to a S-8 registration statement | SEC | |
| 2026-08-10 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing | SEC | |
| 2026-08-10 | 8-A12B/A | SEC | ||
| 2026-08-10 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-28 | SCHEDULE 13G | SEC | ||
| 2026-07-20 | 8-K | Current report | 2026-07-16 | SEC |
| 2026-07-07 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-03 | SEC |
| 2026-06-22 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-17 | 8-K | Current report | 2026-04-28 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G | SEC | ||
| 2026-05-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-08 | 3 | Initial statement of beneficial ownership of securities | 2026-05-01 | SEC |
| 2026-05-04 | 8-K | Current report | 2026-04-28 | SEC |
| 2026-05-01 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 252.88K | 1 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 7.35K | 1 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 23.31K | 3 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| FMR LLC | 15.46% |
| Fairmount Funds Management LLC | 14.15% |
| Avoro Capital Advisors LLC | 6.14% |
| Venrock Adviser, LLC | 5.85% |
| BlackRock, Inc. | 5.14% |
| FCPM III SERVICES B.V. | 3.96% |
| RA CAPITAL MANAGEMENT, L.P. | 3.90% |
| VIKING GLOBAL INVESTORS LP | 3.75% |
| Jupiter Topco LLC | 3.71% |
| Remedium Capital Partners, LLC | 3.32% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Growth Company Fund | 2.97% |
| iShares Russell 2000 ETF | 2.20% |
| Fidelity Small Cap Growth Fund | 1.35% |
| JPMorgan Small Cap Growth Fund | 1.20% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1.16% |
| Fidelity Small Cap Index Fund | 0.95% |
| Fidelity Growth Company K6 Fund | 0.87% |
| Select Health Care Portfolio | 0.81% |
| Fidelity Series Growth Company Fund | 0.74% |
| Select Biotechnology Portfolio | 0.74% |
OakChart. DMRA. Cached 15 minutes. Terms